uploads///Graph Part  Nov

Shire-Dyax Merger Drove Biotech Stocks

By

Nov. 3 2015, Updated 11:51 a.m. ET

Healthcare sector outperformed

The bulls were back on Wall Street after some sluggishness in the market. The month of November began on a positive note with Dow Jones and the S&P 500 gaining 0.95% and 1.2%, respectively, led by the healthcare sector.

Biotech ETFs outperformed the broader market SPDR S&P 500 ETF (SPY), which gave a return of 1.2%. Among the biotech ETFs, the iShares Nasdaq Biotechnology ETF (IBB) rose by 3.9%, and the SPDR S&P Biotech ETF (XBI) rose by 6.6% on November 2, 2015. XBI closed at $70.98 and moved ahead of its 50-day moving average, but still traded below its 100-day moving average.

The above graph reflects the performance of XBI compared to SPY since October 26, 2015, on a day-to-day basis. During this period, XBI has outperformed SPY with a return of ~8.1% as compared to SPY’s return of 1.4%.

Article continues below advertisement

Shire buys Dyax in a deal valued at $5.9 billion

Shire (SHPG) and Dyax (DYAX) announced that SHPG will acquire DYAX for $37.30 per Dyax share in a deal valued at ~$5.9 billion. DYAX shareholders may receive additional value through a non-tradable contingent value right (or CVR) that will pay $4.00 in cash per DYAX share upon approval of DX-2930 in HAE, representing a potential additional $646 million in aggregate contingent consideration. With this acquisition, SHPG will get DYAX’s DX-2930, a drug ready for phase three trials for the treatment of hereditary angioedema (or HAE). The drug will help SHPG in expanding its industry-leading HAE portfolio.

DYAX went up by 28.4% and closed at $35.35 on the merger news. On the contrary, SHPG went down by 1.1% to close at $224.68. The other stocks that gained are Ultragenyx Pharmaceuticals (RARE) and Intercept Pharmaceuticals (ICPT), which gave returns of 10.4% and 7.7%, respectively.

Advertisement

More From Market Realist

    Xr6Iǐx)LKMNIPE,]MKH}`wϞԱyDO;W.W1,qQD M_-B-7 pJDl~399,'r󸺯q} n@$*36?Yp [0XZieGhg|`?d˯NOO6;6 ue|r$㉛шH6#>Y;aA@Q͉KXԵ͎x{ 1I̢ܽXc ,h‘z*'=D}]^t!K(@eB,MiA7WETW>CJݎ N:@lo'z&%^5ا7%S~@c5дAc@Ճz;'Gem*yi D!k%;ʖ l=A5^VO]zW nQhM5 `0=sUqgI*RA;<$ ]FU64ooWw}qsefW+n"'X)}ƒj=yU+l^:vs[J]6ryVr6?Ro_M{2?Ėa 5GD5TN d4<&RvAS*3 v92'̋Et5$ATh Q')XMf3pd]hQY][<5w" !2Z۳Q9ãz@e˨Ui> y|υ Y#pz0L+W/<6Ӱ:}s+`WӀҲ2bt=*I(;ƉVZ2b!5k.dd1ԠL&RӬvǰ#Gߓ8wI/Y.V]ۗy@|g ^@K{VHAa mAbgp{s(4՚$;H t&z]tgHB~쏛 S_Co[R)M7l6zMBZY KK{~S7p}|*6]"-of ݴ6ж?Zx?` CoШ&~1ඟcX Y?#ۙw>{;JĕRTc,>1m~>c41H$@JGZwRiihJN\BN=[WW&{Yи]%hA7sDi٨z^}-b'9z'4#~e1E!)0=|G ^HЬ"Aٙ$
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.